Extract from “How the TPP will restrain the growth of generic medicines and access to affordable medicines”

The collective impact of the TPP on the pharmaceutical industry will be to grant at least 10 years of additional monopoly to innovators in various ways. This may reduce pressure on innovators to research new drugs and develop new remedies. Consequently, the society at large will suffer.

It would also mean that patients in TPP countries would have to continue to pay higher prices for 10 more years. Those who can’t afford these will have to suffer without medicines that could have cured them.

This will in turn slow down the development and commercialisation of generics elsewhere in the world, depriving people of access to affordable medicines.

Loading data

Welcome to TPP Debate!
What's your stance?

TPPDebate.org is a crowd-sourced platform to debate the Trans-Pacific Partnership Agreement (TPP). What does everyone think about the TPP? What is your stance?